MARIA DZIERZKO-TROJANOWSKA: Open Payments
NPI 1093806051 · CHARLESTON, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$553 in 27 payments from 14 companies in 2025. Trend: 2023 $413 · 2024 $767 · 2025 $553
Food & beverage: $553
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 8 | $163 |
| Astellas Pharma US Inc | 2 | $51 |
| Sumitomo Pharma America, Inc. | 2 | $48 |
| ABBVIE INC. | 3 | $45 |
| GlaxoSmithKline, LLC. | 2 | $41 |
| Novo Nordisk Inc | 2 | $33 |
| Philips North America LLC | 1 | $26 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Amgen Inc. | 1 | $22 |
| Abbott Laboratories | 1 | $21 |
Products named: AIRSUPRA, FARXIGA, Veozah, GEMTESA, TRELEGY ELLIPTA, UBRELVY, Ambulatory Monitoring & Diagnostics Undivided, GVOKE HYPOPEN.
Industry payments across SC — which companies pay providers there.
